Phytotherapie versus Hormone bei klimakterischen Beschwerden

Zusammenfassung

Klimakterische Beschwerden können die Lebensqualität außerordentlich beeinträchtigen. Hormonersatztherapie ist zwar bei starken vasomotorischen Symptomen gut wirksam, jedoch haben klinische Studien gezeigt, dass sogar ihre kurzzeitige Anwendung erhebliche Risiken birgt. Die Einnahme von Phytotherapeutika, bei denen eine Wirksamkeit bei Wechseljahresbeschwerden bekannt ist, ist deshalb stark angestiegen. Klinische Studien haben inzwischen gezeigt, dass Präparate aus Mönchspfefferfrüchten, Rhapontikrhabarber, Traubensilberkerzenwurzelstock und Leinsamen sicher und hinsichtlich einer Reihe von Wechseljahressymptomen wirksam sind. Nahrungsergänzungsmitteln mit Soja-Isoflavonen oder Extrakten aus Rotklee scheinen ebenfalls geeignet zu sein.

Abstract

Climacteric discomforts can extremely influence the quality of life. The hormone replacement therapy is very effective in the case of severe vasomotory symptoms, but clinical studies have shown, that even the short-term application of this therapy involves considerable risks. Therefore, the taking of phytotherapeutic agents with a known efficiency in the case of climacteric discomforts has increased considerably. In the meantime, clinical studies have shown, that preparations from fruits of the monks pepper tree, rhubarb (rheum rhaponticum), cimicifuga racemosa, and linseed are safe and effective with respect to a number of climacteric symptoms. Food supplements with soy isoflavones or extracts from red clover also seem to be suitable.

Schlüsselwörter

Menopause - klimakterische Beschwerden - Hormonersatztherapie - HRT - Phytotherapie - Nahrungsergänzungsmittel

Keywords

Menopause - climacteric discomforts - hormone replacement therapy - HRT - phytotherapy - food supplements

• Literatur

• 1 Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold „HRT“. PLoS Medicine 2010; 7 (9) e1000335
• 2 Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280 (7): 605-613
• 3 Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-333
• 4 Barnes BB, Steindorf K, Hein R et al. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiol 2011; 35 (4): 345-352
• 5 Hormontherapie (HT) in der Peri- und Postmenopause. 2009 www.awmf.org/leitlinien/detail/ll/015-062.html
• 6 Vitex. 2011 www.ema.europa.eu
• 7 Daniele C et al. Vitex agnus castus: a systematic review of adverse events. Drug Safety 2005; 28 (4): 319-332
• 8 Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Women’s Health Gend-Based Med 2000; 9 (3): 315-320
• 9 Halaska M, Raus K, Beles P et al. [Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo]. Ceska Gynekol 1998; 63 (5): 388-392
• 10 Wuttke W, Jarry H, Christoffel V et al. Chaste tree (Vitex agnus-castus)--pharmacology and clinical indications. Phytomedicine 2003; 10 (4): 348-357
• 11 He Z, Chen R, Zhou Y et al. Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-center placebo controlled study in China. Maturitas 2009; 63 (1): 99-103
• 12 Berger D, Schaffner W, Schrader E et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 2000; 264 (3): 150-153
• 13 Doll M. [The premenstrual syndrome: effectiveness of Vitex agnus castus]. Medizinische Monatsschrift fur Pharmazeuten 2009; 32 (5): 186-191
• 14 Van Die MD et al. Effects of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. J Altern Complement Med 2009; 15 (9): 1045-1048
• 15 Ma L, Lin S, Chen R et al. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol Endocrinol 2010; 26 (8): 612-616
• 16 Zamani M, Neghab N, Torabian S. Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta medica Iranica 2012; 50 (2): 101-106
• 17 Milewicz AG, Gejdel E, Sworen H et al. Vitex agnus castus-Extrakt zur Behandlung von Regeltempoanomalien infolge latenter Hyperprolaktinämie. Arzneimittelforschung 1993; 43 (7): 752-756
• 18 Kaszkin-Bettag M, Ventskovskiy BM, Solskyy S et al. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms. Altern Ther Health Med 2009; 15 (1): 24-34
• 19 Kaszkin-Bettag M, Ventskovskiy BM, Kravchenko A et al. The special extract ERr 731 of the roots of Rheum rhaponticum decreases anxiety and improves health state and general well-being in perimenopausal women. Menopause 2007; 14 (2): 270-283
• 20 Heger M, Ventskovskiy BM, Borzenko I et al. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. Menopause 2006; 13 (5): 744-759
• 21 Hasper I, Ventskovskiy BM, Rettenberger R et al. Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms. Menopause 2009; 16 (1): 117-131
• 22 Cicek SS, Khom S, Taferner B et al. Bioactivity-guided isolation of GABA(A) receptor modulating constituents from the rhizomes of Actaea racemosa. J Nat Prod 2010; 73 (12): 2024-2028
• 23 Jarry H, Metten M, Spengler B et al. In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas 2003; 44 Suppl 1 p. S 31-38
• 24 Reame NE, Lukacs JL, Padmanabhan V et al. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008; 15 (5): 832-840
• 25 Einbond LS, Wen-Cai Y, He K et al. Growth inhibitory activity of extracts and compounds from Cimicifuga species on human breast cancer cells. Phytomedicine 2008; 15 (6–7): 504-511
• 26 Garita-Hernandez M, Calzado MA, Caballero FJ et al. The growth inhibitory activity of the Cimicifuga racemosa extract Ze 450 is mediated through estrogen and progesterone receptors-independent pathways. Planta Med 2006; 72 (4): 317-323
• 27 Al-Akoum M, Dodin S, Akoum A. Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. Can J Physiol Pharmacol 2007; 85 (11): 1153-1159
• 28 Hostanska K, Nisslein T, Freudenstein J et al. Inhibitory effect of an isopropanolic extract of black cohosh on the invasiveness of MDA-mB 231 human breast cancer cells. In vivo 2007; 21 (2): 349-355
• 29 Hostanska K, Nisslein T, Freudenstein J et al. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat 2004; 84 (2): 151-160
• 30 Nasr A, Nafeh H. Influence of black cohosh (Cimicifuga racemosa) use by postmenopausal women on total hepatic perfusion and liver functions. Fertil Steril 2009; 92 (5): 1780-1782
• 31 Gurley BJ, Barone GW, Wlliams DK et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metabol Dispos 2006; 34 (1): 69-74
• 32 Ross SM. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract 2012; 26 (1): 58-61
• 33 Bai W, Henneicke-von Zepelin HH, Wang S et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007; 58 (1): 31-41
• 34 Oktem M, Eroglu D, Karahan HB et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther 2007; 24 (2): 448-461
• 35 Chung DJ, Kim HY, Park KH et al. Black cohosh and St. John’s wort (GYNO-Plus) for climacteric symptoms. Yonsei Med J 2007; 48 (2): 289-294
• 36 Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007; 23 (2): 117-122
• 37 Newton KM, Reed SD, LaCroix AZ et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006; 145 (12): 869-879
• 38 Uebelhack R, Blohmer JU, Graubaum HJ et al. Black cohosh and St. John’s wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006; 107 (2 Pt 1): 247-255
• 39 Rostock M, Fischer J, Mumm A et al. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecol Endocrinol 2011; 27 (10): 844-848
• 40 Reed SD, Newton KM, LaCroix AZ et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008; 15(1): 51-58
• 41 Spangler L, Newton KM, Grothaus LC et al. The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. Maturitas 2007; 57 (2): 195-204
• 42 Hirschberg AL, Edlund M, Svane G et al. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause 2007; 14 (1): 89-96
• 43 Raus K, Brucker C, Gorkow C et al. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause 2006; 13 (4): 678-691
• 44 Wuttke W, Gorkow C, Seidlova-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006; 13 (2): 185-196
• 45 North American Menopause Society. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011; 18 (7): 732-753
• 46 Taku K, Melby MK, Kronenberg F et al. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause 2012; 19 (7): 776-790
• 47 Lipovac M, Chedraui P, Gruenhut C et al. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women. Gynecol Endocrinol 2012; 28 (3): 203-207
• 48 Coon JT, Pittler MH, Ernst E. Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis. Phytomedicine 2007; 14 (2–3): 153-159
• 49 Pruthi S, Qin R, Terstreip SA et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause 2012; 19 (1): 48-53
• 50 Simbalista RL, Sauerbronn AV, Aldrighi JM et al. Consumption of a flaxseed-rich food is not more effective than a placebo in alleviating the climacteric symptoms of postmenopausal women. J Nutr 2010; 140 (2): 293-297